GH Research PLC (GHRS) director receives 2,202 fully vested share options
Rhea-AI Filing Summary
GH Research PLC director Duncan Moore received a compensatory grant of 2,202 share options on 2026-08-11. The options carry an exercise price of 0.0250 per ordinary share and expire on 2033-08-11. They are immediately fully vested but are not exercisable until August 11, 2028.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Moore Duncan
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Options (Right to Buy) F1 | 2,202 | $0.00 | $0.00 |
Holdings After Transaction:
Share Options (Right to Buy) — 2,202 shares (Direct)
Footnotes (1)
- F1. The share options are immediately fully vested, but are not exercisable until August 11, 2028.
Key Figures
Options granted: 2,202 share options
Exercise price: 0.0250 per share
Underlying shares: 2,202 ordinary shares
+3 more
6 metrics
Options granted
2,202 share options
Grant of share options to director Duncan Moore on 2026-08-11
Exercise price
0.0250 per share
Exercise price for each underlying ordinary share under the options
Underlying shares
2,202 ordinary shares
Number of ordinary shares underlying the granted options
Exercisable date
August 11, 2028
Date from which the options may be exercised, per footnote
Expiration date
2033-08-11
Expiration date of the granted share options
Post-transaction derivative holdings
2,202 options
Total options held from this award following the reported transaction
Key Terms
Share Options (Right to Buy), exercise price, vested, Ordinary Shares
4 terms
exercise price financial
"conversion_or_exercise_price: 0.0250"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested financial
"The share options are immediately fully vested, but are not exercisable"
FAQ
What did GHRS director Duncan Moore report in this Form 4?
Duncan Moore reported a grant of 2,202 share options in GH Research PLC. These options relate to ordinary shares, have an exercise price of 0.0250 per share, and represent a compensation-related acquisition rather than an open-market transaction.
What is the exercise price of the options granted to Duncan Moore at GHRS?
The options granted to Duncan Moore have an exercise price of 0.0250 per share. This price applies to each underlying ordinary share that can be purchased upon exercise, according to the derivative transaction reported in the Form 4.
When do Duncan Moore’s GHRS options become exercisable and when do they expire?
The options are not exercisable until August 11, 2028, as specified in the footnote. They carry an expiration date of 2033-08-11, providing a multi-year window for potential exercise after becoming exercisable.
Are the GHRS options granted to Duncan Moore vested immediately?
Yes. A footnote states the share options are immediately fully vested. However, despite being fully vested, they cannot be exercised until August 11, 2028, creating a gap between vesting and exercisability for this award.
Is Duncan Moore’s GHRS Form 4 transaction a buy or a grant?
The Form 4 identifies the transaction as a grant or award acquisition of derivative securities under code A. It is not reported as an open-market purchase or sale, but rather as a compensation-related option grant directly owned by the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
